Navigation Links
Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia
Date:3/26/2012

 

p=0.59

p=0.42Responder Analysis 

 

 

 "Much Improved or Very Much Improved" 

 

 

   Clinical Global Impression-Tardive Dyskinesia

n/a

52%

65%

60%  Patient Global Impression of Change

n/a

39%

53%

60%  Excluding Single Site Baseline(mean)Placebo12.5mg50mgAbnormal Involuntary Movement Scale (LS Means)14.9

10.3

9.9

6.1 

 

 

p=0.68

p=0.002Responder Analysis end of Treatment 

 

 

 "Much Improved or Very Much Improved" 

 

 

 Clinical Global Impression-Tardive Dyskinesia

n/a

46%

67%

80%Patient Global Impression of Change

n/a

38%

62%

80%Safety ProfileNBI-98854 was generally safe and well tolerated; the frequency of treatment-emergent adverse events was 17% during the placebo period and 24% and 32% in the 12.5mg and 50mg treatment periods, respectively. There were no serious adverse events during the treatment period. The most common adverse event was headache and one subject in the 50mg group discontinued due to akathisia. The underlying psychiatric state of subjects was monitored using the Brief Psychiatric Ratings Scale (BPRS) and shown to be stable or improved across study groups declining from 32 at baseline to 28 at the end of the study. There were no drug-drug interactions identified in subjects who were utilizing a range of psychotropic and other concomitant medications.

"While not ideal, this study served its primary purpose of informing the larger Phase IIb studies. The 50mg once-daily dose of NBI-98854 provided tardive dyskinesia sufferers with a remarkable improvement of symptoms, coupled with an excellent
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock
2. Neurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock
3. Neurocrine Mourns the Passing of Founder and Board Member Wylie Vale, Ph.D.
4. Neurocrine Biosciences to Present at the 30th Annual J.P. Morgan Healthcare Conference
5. Neurocrine Biosciences to Present at the 23rd Annual Piper Jaffray Health Care Conference
6. Neurocrine Biosciences to Present at the 2011 Credit Suisse Annual Health Care Conference
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2011 Financial Results
8. Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement
9. Neurocrine Biosciences Announces Elagolix Scientific Presentations at the 67th Annual Meeting of the American Society for Reproductive Medicine
10. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
11. Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... LONDON , July 23, 2014  Lightlake ... developing addiction treatments based on its expertise in ... an investigational new drug application ("IND") with respect ... Lightlake also announced today that it has received ... Drug Abuse ("NIDA"), part of the National Institutes ...
(Date:7/23/2014)... , July 23, 2014  Silk Road ... the transcarotid treatment of intra- and extra-cranial cerebrovascular ... P. Wallace to the position of Chief ... lead the company,s Research and Development efforts across ... Prior to joining Silk Road ...
(Date:7/23/2014)... , July 23, 2014  ACON Equity Partners III, ... Investments, L.L.C. ("ACON") announced it has completed the purchase ... from Audax Group and Parthenon Capital Partners. IWP is ... billion Workers, Compensation, Automobile Personal Injury Protection and Personal ... . As part of this ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 3ACON Investments Acquires Injured Workers Pharmacy 2ACON Investments Acquires Injured Workers Pharmacy 3
... Therapeutics, Inc. (Nasdaq: ECTE ), a company ... wireless, transdermal continuous glucose monitoring system and its Prelude® ... results for the year ended December 31, 2011.  Echo,s ... website at www.echotx.com . 2011 ...
...   Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) ... of senior vice president and chief commercial officer. Mr. Palekar ... activities. "Rohan has an outstanding track record of ... president and CEO of Avanir. "I am delighted that we ...
Cached Medicine Technology:Echo Therapeutics, Inc. Announces 2011 Financial Results 2Echo Therapeutics, Inc. Announces 2011 Financial Results 3Echo Therapeutics, Inc. Announces 2011 Financial Results 4Echo Therapeutics, Inc. Announces 2011 Financial Results 5Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer 2Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer 3
(Date:7/23/2014)... -- For patients infected with both HIV and hepatitis ... viruses, a small study suggests. Researchers said doctors ... people with the two diseases. "The findings ... important role in the management of individuals with [hepatitis ... Sherman, a professor of medicine at the University of ...
(Date:7/23/2014)... Cancer is a disease of the genome resulting from ... from our parents strong or weak predispositions to developing ... new mutations in our cells throughout our lifetime. Although ... a long time, researchers were not able to measure ... now. A team of geneticists from the University of ...
(Date:7/23/2014)... MI (PRWEB) July 23, 2014 Ticket ... Madrid vs. Manchester United tickets at Michigan Stadium . ... International Champions Cup will be held at the Big House ... of Michigan Wolverines, will be home to a game between ... from La Liga. The game will be held on August ...
(Date:7/23/2014)... NJ (PRWEB) July 23, 2014 CarePoint ... the first hospital in New Jersey to receive the ... advanced robotics platform in the da Vinci series. This ... a profound step forward in innovation. The intuitive da ... across a wide spectrum of minimally invasive and complex ...
(Date:7/23/2014)... This report defines and segments the "EHV ... Middle East & Africa, and Americas) - Global Trends ... analysis and forecasts of the global revenue. The global ... $10 billion in 2014 to nearly $14 billion by ... browse 49 Market Tables and 10 Figures Spread Through ...
Breaking Medicine News(10 mins):Health News:HIV Meds May Also Help Control Hepatitis C, Study Finds 2Health News:Genetics of cancer: Non-coding DNA can finally be decoded 2Health News:Real Madrid vs. Manchester United Tickets Ann Arbor: Ticket Down Slashes Ticket Prices for ManU vs. Real Madrid Guinness International Champions Cup Tickets 2Health News:Real Madrid vs. Manchester United Tickets Ann Arbor: Ticket Down Slashes Ticket Prices for ManU vs. Real Madrid Guinness International Champions Cup Tickets 3Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 2Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 3Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 4Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 2Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 3Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 4
... Mass., Oct. 30 Repligen Corporation,(Nasdaq: RGEN ) ... Walter C. Herlihy, Ph.D., will host a conference call,and ... EST, to report,second quarter fiscal year 2009 financial results ... This call is being webcast by Thomson/CCBN and can ...
... Prices, According To New Data ... from Arlington Medical Resources, MALVERN, Penn., Oct. 30 ... the pharmaceutical and,diagnostic imaging industries, finds that echinocandins show growth in ... courses,in the January - June 2008 time period compared to 9 ...
... Visit Washington D.C. to Rally Residents to Eat Right, Move ... More and Milk Their ... by,the ups and downs of different fad diets -- which seem to ... success has been,slim. Two out of three Americans -- including 22% of ...
... Mid-Atlantic Region, ATLANTA, Oct. 30 AmeriCare ( ... the opening of its,latest franchises serving Howard, Montgomery, and ... states in the union, Maryland is in the,top 20 ... Marylanders is over the,age of 60. AmeriCare of Maryland ...
... MIAMI, Oct. 30 Physicians Healthcare,Management Group, Inc. (Phyhealth) ... in partnership with physicians,today announced that its board of ... to 5% of the Company,s outstanding Common Stock., ... at the market price.,The purchases will be made at ...
... MED ) announced today that it will release third quarter ... 30, 2008 on,Thursday, November 6, 2008. The Company will hold ... Thursday, November 6, at 11:00 a.m. ET., Interested parties ... or can listen via a live Internet web cast, which ...
Cached Medicine News:Health News:Repligen Announces Conference Call of Second Quarter Fiscal Year 2009 Results Thursday, November 6th, 10:00 a.m. EST 2Health News:Repligen Announces Conference Call of Second Quarter Fiscal Year 2009 Results Thursday, November 6th, 10:00 a.m. EST 3Health News:Echinocandins Show Growth Among All Antifungal Classes 2Health News:Echinocandins Show Growth Among All Antifungal Classes 3Health News:Message to Washington D.C. Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Washington D.C. Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Caregiving Company AmeriCare Adds Franchise in Maryland 2Health News:Phyhealth Announces Stock Buyback Program 2Health News:Phyhealth Announces Stock Buyback Program 3Health News:Medifast, Inc. to Announce Third Quarter of Fiscal Year 2008 Financial Results on Thursday, November 6, 2008 2
... drive system which eliminates many of ... out. There are no motor brushes, ... drive belts - resulting in a ... carry weights up to 400 pounds. ...
... The Quinton Q-Stress Cardiac Stress ... baseline wander and muscle artifact ... second to provide the highest ... Leads can be displayed in ...
... ECT WS 2000 is designed to monitor, ... cardiovascular provocative tests, (stress-testing). The system can organize ... and provide them for a quick review and ... ,The recorded ECG is transmitted via a small ...
... compact BioStress 2000 is a software driven, ... testing system. The BioStress 2000 program is ... viewing, permanent ECG strorage and retrieval and ... printer. BioStress 2000 allows a wide range ...
Medicine Products: